二甲双胍治疗肺气肿的实验与临床证据
该研究通过慢性香烟烟雾暴露小鼠模型和COPDGene队列分析,探讨二甲双胍对肺气肿性COPD的保护作用。小鼠实验显示二甲双胍可减轻肺部炎症、气腔扩大及全身性损伤,机制涉及AMPK通路;COPDGene队列中,使用二甲双胍者肺气肿进展更慢(-0.92%,95%CI -1.7%至-0.14%,P=0.02),调整后肺密度下降更缓(2.2 g/L,95%CI 0.43至4.0 g/L,P=0.01)。结果提示二甲双胍可能延缓肺气肿进展,为临床试验提供依据。
要点
- 二甲双胍减轻香烟烟雾诱导的小鼠肺气肿和全身损伤,AMPK通路是关键。
- COPDGene队列中,二甲双胍使用与肺气肿进展减慢及肺密度下降减缓相关。
- 结果为临床试验验证二甲双胍延缓肺气肿进展的疗效提供依据。
核心结论
- 二甲双胍可保护小鼠免受香烟烟雾诱导的肺、肾、肌肉损伤及线粒体功能障碍和内质网应激。
- 在人类中,二甲双胍使用与肺气肿进展较慢相关。
- 结果支持开展临床试验测试二甲双胍限制肺气肿进展及其全身后果的疗效。
研究设计与样本
- 小鼠慢性暴露于香烟烟雾,后半程喂食富二甲双胍饲料,研究肺、肾、肌肉病理及肺蛋白质稳态等。
- 在COPDGene研究参与者中评估二甲双胍使用与5年随访期间肺气肿进展指标的关联。
- 采用线性混合模型估计二甲双胍使用与肺气肿百分比及调整后肺密度的关联。
主要发现
- 二甲双胍保护小鼠免受香烟烟雾诱导的肺部炎症和空气腔扩大。
- 二甲双胍减轻小气道重塑、肾小球萎缩、氧化应激、凋亡、端粒损伤、衰老、代谢异常及内质网应激。
- AMPK通路是二甲双胍保护作用的核心。
- COPDGene中,使用二甲双胍者肺气肿进展较未使用者慢(-0.92%;95%CI -1.7%至-0.14%;P=0.02)。
- 使用二甲双胍者调整后肺密度下降较慢(2.2 g/L;95%CI 0.43至4.0 g/L;P=0.01)。
临床怎么用
- 二甲双胍可能作为延缓肺气肿进展的潜在治疗选择,但需临床试验验证。
- 对COPD患者使用二甲双胍时,可关注其对肺气肿进展的潜在益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Cigarette smoke (CS) inhalation triggers oxidative stress and inflammation, leading to accelerated lung aging, apoptosis, and emphysema, as well as systemic pathologies. Metformin is beneficial for protecting against aging-related diseases. Objectives: We sought to investigate whether metformin may ameliorate CS-induced pathologies of emphysematous chronic obstructive pulmonary disease (COPD). Methods: Mice were exposed chronically to CS and fed metformin-enriched chow for the second half of exposure. Lung, kidney, and muscle pathologies, lung proteostasis, endoplasmic reticulum (ER) stress, mitochondrial function, and mediators of metformin effects in vivo and/or in vitro were studied. We evaluated the association of metformin use with indices of emphysema progression over 5 years of follow-up among the COPDGene (Genetic Epidemiology of COPD) study participants. The association of metformin use with the percentage of emphysema and adjusted lung density was estimated by using a linear mixed model. Measurements and Main Results: Metformin protected against CS-induced pulmonary inflammation and airspace enlargement; small airway remodeling, glomerular shrinkage, oxidative stress, apoptosis, telomere damage, aging, dysmetabolism in vivo and in vitro; and ER stress. The AMPK (AMP-activated protein kinase) pathway was central to metformin's protective action. Within COPDGene, participants receiving metformin compared with those not receiving it had a slower progression of emphysema (-0.92%; 95% confidence interval [CI], -1.7% to -0.14%; P = 0.02) and a slower adjusted lung density decrease (2.2 g/L; 95% CI, 0.43 to 4.0 g/L; P = 0.01). Conclusions: Metformin protected against CS-induced lung, renal, and muscle injury; mitochondrial dysfunction; and unfolded protein responses and ER stress in mice. In humans, metformin use was associated with lesser emphysema progression over time. Our results provide a rationale for clinical trials testing the efficacy of metformin in limiting emphysema progression and its systemic consequences.
引用
- Polverino F, Wu TD, Rojas-Quintero J, et al. Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. Am J Respir Crit Care Med. 2021. PMID: 34033525. doi:10.1164/rccm.202012-4510OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。